• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Biocept Inc.

    6/2/23 4:26:13 PM ET
    $BIOC
    Medical Specialities
    Health Care
    Get the next $BIOC alert in real time by email
    SC 13G 1 sc13g.htm

     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
         
         
         
     
    SCHEDULE 13G
     
     
     
    Under the Securities Exchange Act of 1934
     
     
     
    (Amendment No.   )*
     
         
     
    Biocept, Inc.
     
     
    (Name of Issuer)
     
         
     
    Common Stock, par value $0.0001 per share
     
     
    (Title of Class of Securities)
     

     
    09072V600
     
     
    (CUSIP Number)
     

     
    May 26, 2023
     
     
    (Date of Event which Requires Filing of this Statement)
     


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    [ ]
    Rule 13d-1(b)
     
    [x]
    Rule 13d-1(c)
     
    [ ]
    Rule 13d-1(d)
     






    ___________________________________
    *  The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
     
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     

    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)

    Lind Global Fund II LP

    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Delaware
    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power

    147,294
    6  Shared Voting Power
     
    0
    7  Sole Dispositive Power
     
    147,294
    8  Shared Dispositive Power
     
    0
    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    147,294(1)
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    9.9%(2)
    12
    Type of Reporting Person (See Instructions)

    PN
    (1) The reporting person’s ownership consists of (i) 135,294 shares of common stock, (ii) 100,000 warrants to purchase shares of common stock (“Pre-funded Warrants”), and (iii) 470,588 warrants to purchase shares of common stock (the “2023 Warrants,” together with the Pre-funded Warrants, the “Warrants”); however, due to the exercise limitations of the Warrants, the reporting person’s beneficial ownership has been limited to 147,294 shares in the aggregate.
    (2) Each of the Warrants includes a provision limiting the holder’s ability to exercise the Warrants if such exercise would cause the holder to beneficially own greater than 9.99% of the Company.


    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)

    Lind Global Partners II LLC

    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Delaware
    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
     
    147,294
    6  Shared Voting Power
     
    0
    7  Sole Dispositive Power
     
    147,294
    8  Shared Dispositive Power
     
    0
    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    147,294(1)
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    9.9%(2)
    12
    Type of Reporting Person (See Instructions)

    OO
    (1) The reporting person’s ownership consists of (i) 135,294 shares of common stock, (ii) 100,000 Pre-funded Warrants, and (iii) 470,588 2023 Warrants; however, due to the exercise limitations of the Warrants, the reporting person’s beneficial ownership has been limited to 147,294 shares in the aggregate.
    (2) Each of the Warrants includes a provision limiting the holder’s ability to exercise the Warrants if such exercise would cause the holder to beneficially own greater than 9.99% of the Company.


    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
     
    Jeff Easton

    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    United States
    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
     
    147,294
    6  Shared Voting Power
     
    0
    7  Sole Dispositive Power
     
    147,294
    8  Shared Dispositive Power
     
    0
    9
    Aggregate Amount Beneficially Owned by Each Reporting Person

    147,294(1)
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    9.9%(2)
    12
    Type of Reporting Person (See Instructions)
     
    IN
    (1) The reporting person’s ownership consists of (i) 135,294 shares of common stock, (ii) 100,000 Pre-funded Warrants, and (iii) 470,588 2023 Warrants; however, due to the exercise limitations of the Warrants, the reporting person’s beneficial ownership has been limited to 147,294 shares in the aggregate.
    (2) Each of the Warrants includes a provision limiting the holder’s ability to exercise the Warrants if such exercise would cause the holder to beneficially own greater than 9.99% of the Company.


    Item 1.
     
     
    (a)
    Name of Issuer
       
     
    Biocept, Inc.
     
    (b)
    Address of Issuer’s Principal Executive Offices
       
     
    9955 Mesa Rim Road,
    San Diego, CA 92121
     

    Item 2.
     
     
    (a)
    Name of Person Filing
       
     
    This statement is filed by the following entities and individuals (collectively, referred to as the “Reporting Persons”):
     
    •   Lind Global Fund II LP, a Delaware limited partnership;
    •   Lind Global Partners II LLC, a Delaware limited liability company; and
    •   Jeff Easton, an individual and a citizen of the United States of America.
     
    Lind Global Partners II LLC, the general partner of Lind Global Fund II LP, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund II LP.
     
    Jeff Easton, the managing member of Lind Global Partners II LLC, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund II LP.
     
     
    (b)
    Address of Principal Business Office or, if none, Residence
       
     
    The address of the principal business office for each of the Reporting Persons is:
     
    444 Madison Ave, Floor 41
    New York, NY 10022
     
     
    (c)
    Citizenship
       
     
    See Row 4 of cover page for each Reporting Person.
     
     
    (d)
    Title of Class of Securities
         
       
    Common Stock, par value $0.0001 per share
         
     
    (e)
    CUSIP Number
       
     
    09072V600
     

    Item 3.
    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    Not applicable.
     
    Item 4.
    Ownership
     
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
     
     
    (a)
    Amount Beneficially Owned
       
     
     See Row 9 of cover page for each Reporting Person.
     
     
    (b)
    Percent of Class
       
     
    See Row 11 of cover page for each Reporting Person.
     

     
    (c)
    Number of shares as to which such person has:
     
       
    (i)
    sole power to vote or to direct the vote
         

    See Row 5 of cover page for each Reporting Person.
     
       
    (ii)
    shared power to vote or to direct the vote
         
     
    See Row 6 of cover page for each Reporting Person.
     
       
    (iii)
    sole power to dispose or to direct the disposition of
         

    See Row 7 of cover page for each Reporting Person.
     
       
    (iv)
    shared power to dispose or to direct the disposition of
         
     
    See Row 8 of cover page for each Reporting Person.
     
     
     
    Item 5.
    Ownership of Five Percent or Less of a Class
     
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.
     

    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person

    Not applicable.
     
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

    Not applicable.
     
    Item 8.
    Identification and Classification of Members of the Group

    Not applicable.
     
    Item 9.
    Notice of Dissolution of Group

    Not Applicable.
     
    Item 10.
    Certification
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    Exhibits
    Exhibit
     
    99.1
    Joint Filing Agreement by and among the Reporting Persons.
     

    SIGNATURE
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
    June 2, 2023
     
    LIND GLOBAL FUND II LP
       
    By:
     
    Lind Global Partners II LLC
     
     
    its General Partner
       
    By:
     
    /s/ Jeff Easton
    Name:
     
    Jeff Easton
    Title:
     
    Managing Member
     
    LIND GLOBAL PARTNERS II LLC
       
    By:
     
    /s/ Jeff Easton
    Name:
     
    Jeff Easton
    Title:
     
    Managing Member
     
    JEFF EASTON
     
    By:
     
    /s/ Jeff Easton


    Get the next $BIOC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BIOC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BIOC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Biocept Inc.

      SC 13G - BIOCEPT INC (0001044378) (Subject)

      6/2/23 4:26:13 PM ET
      $BIOC
      Medical Specialities
      Health Care

    $BIOC
    Leadership Updates

    Live Leadership Updates

    See more
    • Enrollment Completed in the Feasibility Phase of the FORESEE Clinical Trial with Biocept's CNSide™ Assay to Evaluate Patients with Leptomeningeal Metastases

      Biocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, announces the full enrollment of 40 subjects with breast or non-small cell lung cancer (NSCLC) who have suspicious or confirmed leptomeningeal metastases (LM) in the feasibility phase of its prospective FORESEE clinical trial (NCT0414123). This trial is evaluating the performance of Biocept's proprietary CNSide assay in monitoring the response to therapy of LM, a cancer in the membranes that surround the brain and spinal cord, and assessing its impact on treatment decisions made by physicians. "Completing enrollment in this first phase of our FORESEE trial, and doing so ahead of our inte

      9/21/23 8:00:00 AM ET
      $BIOC
      Medical Specialities
      Health Care
    • Biocept Names Antonino Morales as President and Chief Executive Officer

      Samuel D. Riccitelli resigns as interim President and CEO, and Director Biocept, Inc. (NASDAQ:BIOC) ("Biocept" or the "Company"), a leading provider of molecular diagnostic assays, products and services, has named Antonino Morales as President and Chief Executive Officer, effective immediately. Mr. Morales has served as Biocept's interim Chief Financial Officer since February 2022 and as a Director of the Company since July 2021. Robert Walsh, the Company's Controller, has been promoted to Vice President and Controller and will serve as the Company's principal accounting officer. These changes follow the resignation of Samuel D. Riccitelli as interim President and Chief Executive Officer,

      6/20/23 4:15:00 PM ET
      $BIOC
      Medical Specialities
      Health Care
    • Biocept Appoints Financial Executive Quyen Dao-Haddock to its Board of Directors

      Biocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, announces the appointment of Quyen Dao-Haddock to its Board of Directors, effective immediately, increasing Board membership to eight. Ms. Dao-Haddock is a certified public accountant (CPA) with more than 20 years of financial and accounting experience. She will serve on Biocept's Audit Committee. "Quyen's extensive financial experience leading accounting and finance departments, and overseeing technical accounting, budgeting and forecasting, financial modeling, cash management and SEC reporting, make her a valuable addition to our Board and its Audit Committee," said Samuel D. Riccitelli

      11/18/22 8:00:00 AM ET
      $BIOC
      Medical Specialities
      Health Care

    $BIOC
    Financials

    Live finance-specific insights

    See more
    • Biocept to Hold Business Update Conference Call on August 30, 2023

      Biocept, Inc. (NASDAQ:BIOC) management will hold a conference call on August 30, 2023, beginning at 4:00 p.m. Eastern time (1:00 p.m. Pacific time) to provide a business update and to answer questions. Participants can pre-register for the conference call here. Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time. The conference call can be accessed at the time of the live call by dialing (855) 656-0927 for domestic callers, (855) 669-9657 for Canadian callers or (412) 902-4109 for other international callers.

      8/25/23 8:00:00 AM ET
      $BIOC
      Medical Specialities
      Health Care
    • Biocept Reports First Quarter 2023 Financial Results

      Biocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three months ended March 31, 2023 and provides a business update. "I'm exceptionally pleased with the progress being made with our FORESEE clinical trial, which is specifically designed to generate evidence of CNSide™'s clinical utility to support adoption into clinical care guidelines and further broaden physician use. Trial enrollment is running well in line with our plan, and we've now activated clinical sites in Dallas, Los Angeles and the San Francisco Bay Area," said Samuel D. Riccitelli, Biocept's Chairman, and interim President and CEO. "In our q

      5/10/23 4:05:00 PM ET
      $BIOC
      Medical Specialities
      Health Care
    • Biocept Reports 2022 Financial Results

      Biocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the 12 months ended December 31, 2022 and provides a business update. "I could not be prouder of my Biocept colleagues as together we have worked tirelessly to streamline operations, prioritize decisions to advance our corporate mission and carefully manage expenditures. We are more convinced than ever that our proprietary CNSide™ assay will improve the lives of patients with cancers that have metastasized to the central nervous system. To support this conviction, we have completed our evaluation of strategic alternatives and determined that the best course

      4/17/23 4:10:00 PM ET
      $BIOC
      Medical Specialities
      Health Care

    $BIOC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Enrollment Completed in the Feasibility Phase of the FORESEE Clinical Trial with Biocept's CNSide™ Assay to Evaluate Patients with Leptomeningeal Metastases

      Biocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, announces the full enrollment of 40 subjects with breast or non-small cell lung cancer (NSCLC) who have suspicious or confirmed leptomeningeal metastases (LM) in the feasibility phase of its prospective FORESEE clinical trial (NCT0414123). This trial is evaluating the performance of Biocept's proprietary CNSide assay in monitoring the response to therapy of LM, a cancer in the membranes that surround the brain and spinal cord, and assessing its impact on treatment decisions made by physicians. "Completing enrollment in this first phase of our FORESEE trial, and doing so ahead of our inte

      9/21/23 8:00:00 AM ET
      $BIOC
      Medical Specialities
      Health Care
    • Biocept Signs CNSide™ Licensing Agreement with Plus Therapeutics

      Biocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products, and services, announces the signing of a non-exclusive licensing agreement for CNSide™ with Plus Therapeutics, Inc. (NASDAQ:PSTV) (Plus), which expands the comprehensive laboratory services agreement between the two companies that was announced in June 2022. Plus is using CNSide in a clinical trial with their targeted radiotherapeutic to treat patients with carcinomas and/or melanomas with suspected leptomeningeal metastases (LM), which is cancer in the membranes that surround the brain and spinal cord. CNSide is Biocept's proprietary cerebrospinal fluid (CSF)-based tumor cell capture and enumeration p

      9/8/23 8:00:00 AM ET
      $BIOC
      $PSTV
      Medical Specialities
      Health Care
      Medical/Dental Instruments
    • Biocept to Participate in the H.C. Wainwright Global Investment Conference

      Biocept, Inc. (NASDAQ:BIOC) ("Biocept" or the "Company"), a leading provider of molecular diagnostic assays, products and services, announces that management will participate in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023. A webcast of the Biocept presentation will be available on the Events & Presentation section of the Company's website beginning Monday, September 11 at 7:00 a.m. Eastern time. Management is available throughout the conference for virtual one-on-one meetings. Institutional investors and industry professionals can register to attend the conference virtually or in-person at the Lotte New York Palace Hotel. About Biocept

      9/5/23 8:00:00 AM ET
      $BIOC
      Medical Specialities
      Health Care

    $BIOC
    SEC Filings

    See more
    • Biocept Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - BIOCEPT INC (0001044378) (Filer)

      10/20/23 6:06:21 AM ET
      $BIOC
      Medical Specialities
      Health Care
    • Biocept Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Leadership Update

      8-K - BIOCEPT INC (0001044378) (Filer)

      10/16/23 8:53:52 AM ET
      $BIOC
      Medical Specialities
      Health Care
    • Biocept Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - BIOCEPT INC (0001044378) (Filer)

      8/22/23 4:10:54 PM ET
      $BIOC
      Medical Specialities
      Health Care

    $BIOC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Walsh Robert

      3 - BIOCEPT INC (0001044378) (Issuer)

      6/20/23 7:09:58 PM ET
      $BIOC
      Medical Specialities
      Health Care
    • SEC Form 4 filed by Dao-Haddock Quyen Thi

      4 - BIOCEPT INC (0001044378) (Issuer)

      11/18/22 8:26:29 PM ET
      $BIOC
      Medical Specialities
      Health Care
    • SEC Form 3 filed by new insider Dao-Haddock Quyen Thi

      3 - BIOCEPT INC (0001044378) (Issuer)

      11/18/22 8:22:42 PM ET
      $BIOC
      Medical Specialities
      Health Care